The content on this site is intended for healthcare professionals only
Pivotal phase II trial of ponatinib in patients with chronic myeloid leukaemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph ALL) resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL mutation: 12-Month Follow-up of the PACE trial
Researchers have discovered that ponatinib, a new oral tyrosine-kinase inhibitor (TKI), can silence a deadly mutation in chronic myeloid leukaemia (CML) and Philadelphia chromosome-positive acute lymphocytic leukaemia (Ph ALL).
From an official ASH 2012 Press Conference.
Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
Multiple myeloma in a resource constrained setting
Significant clinical benefits observed with revumenib monotherapy in relapsed/refractory KMT2Ar acute leukaemia
Ide-cell enhances health-related quality of life for refractory multiple myeloma
